Team:BrownTwo/Implementation/syntf

From 2008.igem.org

(Difference between revisions)
Line 17: Line 17:
=The Biofusion Standard=
=The Biofusion Standard=
-
Compared to other fields in biology, synthetic biology devotes a considerable amount of attention towards the standardization of parts and of practice.  The inspiration for such a focus stems from similar concepts in engineering, which depends upon well-characterized systems for the design of complex systems that behave reliably according to predictions.  Indeed, as readers of this wiki may be well aware, the iGEM competition focuses on the use of the Biobrick standard, which is an idempotent approach to cloning recombinant DNA.  The Biobrick standard constitutes a conserved sequence of sites that envelop a genetic part, whether it be a coding gene, a promoter, or some other functional piece of DNA.   
+
Compared to other fields in biology, synthetic biology devotes a considerable amount of attention towards the standardization of parts and of practice.  The inspiration for such a focus stems from similar concepts in engineering, which depends upon well-characterized systems for the design of complex systems that behave reliably according to predictions.  Indeed, as readers of this wiki may be well aware, the iGEM competition focuses on the use of the Biobrick standard, which is an idempotent approach to cloning recombinant DNA.  The Biobrick standard constitutes a conserved sequence of restriction enzyme cut sites that envelop a genetic part, whether it be a coding gene, a promoter, or some other functional piece of DNA.  The
-
Our synthetic transcription factors were designed according to a  
+
Our synthetic transcription factors were designed according to a Biofusion standard, which was developed by the Silver lab at Harvard for the purpose of constructing these parts.
-
The differences between the two standards are minimal.  In fact, the method of ligating two parts proves to be exactly the same, regardless of whether the part is destined to become a prefix or a suffix to another.  Such a result is a consequence of the fact that the two standards share a similar  However,  
+
The differences between the two standards are minimal.  In fact, the method of ligating two parts proves to be exactly the same, regardless of whether the part is destined to become a prefix or a suffix to another.  Such a result is a consequence of the fact that the two standards share an identical layout of restriction digest sites.  However, a close-up investigation of the interface that occurs when two parts from each scheme are ligated together. 
-
[[image:Biobrickin'.jpg|center|900px]]
+
As one can see in the diagram, intrinsic to the Biobrick standard is a spacing nucleotide between the part and each of the adjacent restriction sites, namely XbaI and SpeI.  When two such parts are ligated together according to the Standard Assembly procedure, exactly one spacer nucleotide from each Biobrick is maintained in the final part.  The result is that a total of eight nucleotides lie between , comprised of these two spacers plus the hybrid 
 +
 
 +
 
 +
 
 +
[[image:Biobrickin'.jpg|thumb|center|900px]]
[[image:Biofusion.jpg|center|900px]]
[[image:Biofusion.jpg|center|900px]]
 +
 +
By nature of how it is designed, the Biobrick standard affords a great deal of modularity to those who use parts .  Thus, the Biofusion provides for an even more customizable system by allowing for the creation of fusion proteins, hybrid proteins formed by the fusion of two protein domains to one another.  This modularity for protein design lies at the heart of our limiter device. 
Modularity – in order to modify the design to limit the expression of a given gene of interest, one must study a gene pathway map and identify a single link between the gene of interest and a transcription factor that regulates the expression of that gene
Modularity – in order to modify the design to limit the expression of a given gene of interest, one must study a gene pathway map and identify a single link between the gene of interest and a transcription factor that regulates the expression of that gene

Revision as of 18:01, 29 October 2008



Transcription factors

The syn. trans. factor system designed by caroline & david. cite memory.

  • modularity
  • extensibility

The laboratory of Dr. Pamela Silver at Harvard developed synthetic transcription factors for the construction of a novel “memory device” in Saccharomyces cerevisiae. While the details of this device are not essential to understanding our own gene network, it is important to discuss the significance of these transcription factors to our design. A transcription factor is composed of a binding domain, which targets the protein either an activation domain or a repression domain, which

Transcription factors are composed of a standard activation or repression domain linked to a variable binding domain. The binding domain is chosen such that it matches. Other features of these . A handful of these parts were available in the Registry, but we found it necessary to


The Biofusion Standard

Compared to other fields in biology, synthetic biology devotes a considerable amount of attention towards the standardization of parts and of practice. The inspiration for such a focus stems from similar concepts in engineering, which depends upon well-characterized systems for the design of complex systems that behave reliably according to predictions. Indeed, as readers of this wiki may be well aware, the iGEM competition focuses on the use of the Biobrick standard, which is an idempotent approach to cloning recombinant DNA. The Biobrick standard constitutes a conserved sequence of restriction enzyme cut sites that envelop a genetic part, whether it be a coding gene, a promoter, or some other functional piece of DNA. The

Our synthetic transcription factors were designed according to a Biofusion standard, which was developed by the Silver lab at Harvard for the purpose of constructing these parts.

The differences between the two standards are minimal. In fact, the method of ligating two parts proves to be exactly the same, regardless of whether the part is destined to become a prefix or a suffix to another. Such a result is a consequence of the fact that the two standards share an identical layout of restriction digest sites. However, a close-up investigation of the interface that occurs when two parts from each scheme are ligated together.

As one can see in the diagram, intrinsic to the Biobrick standard is a spacing nucleotide between the part and each of the adjacent restriction sites, namely XbaI and SpeI. When two such parts are ligated together according to the Standard Assembly procedure, exactly one spacer nucleotide from each Biobrick is maintained in the final part. The result is that a total of eight nucleotides lie between , comprised of these two spacers plus the hybrid


Biobrickin'.jpg
Biofusion.jpg


By nature of how it is designed, the Biobrick standard affords a great deal of modularity to those who use parts . Thus, the Biofusion provides for an even more customizable system by allowing for the creation of fusion proteins, hybrid proteins formed by the fusion of two protein domains to one another. This modularity for protein design lies at the heart of our limiter device.

Modularity – in order to modify the design to limit the expression of a given gene of interest, one must study a gene pathway map and identify a single link between the gene of interest and a transcription factor that regulates the expression of that gene

Stipulation: If G is a transcription factor that is known to auto-regulate, one will have to alter the modeling to account for this situation.

modifications to current scheme:

  • Ribozyme switch inhibition to knockdown leakiness of Repressor#3 (this would need to designed so that the aptamer on the repressor #3 mRNA responds to Repressor #2 protein)
  • alternatively, could consider having the promoter for construct Y produce an shRNA instead of a repressor protein
  • need to consider the possibility for regulation on both levels of protein synthesis

Possible further modifications to these transcription factors include the use of different regulation domains,

Involves the consideration of multiple binding sites